Showing results (81-90 of 92) with videos related to
Sort By:
Pageof 10
Journal of Thrombosis and Haemostasis : JTH|June 20, 2019
Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variabilityVirginie Siguret, Johan Abdoul, Xavier Delavenne, et al.Thrombosis and Haemostasis|November 17, 2022
Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly PatientsGeoffrey Foulon-Pinto, Carmelo Lafuente-Lafuente, Georges Jourdi, et al.Journal of Thrombosis and Haemostasis : JTH|July 17, 2024
Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center studyIsabelle Gouin-Thibault, Alexandre Mansour, Charlène Caribotti, et al.Research and Practice in Thrombosis and Haemostasis|June 11, 2025
Management of bleeding and invasive procedures in patients treated with anti-factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and HaemostasisAnne Godier, Dominique Lasne, Anne-Céline Martin, et al.Journal of Thrombosis and Haemostasis : JTH|May 18, 2024
The use of 1E12, a monoclonal anti-platelet factor 4 antibody, to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopeniaCaroline Vayne, Jérôme Rollin, Rumi Clare, et al.Chest|January 19, 2021
Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 PneumoniaCharles Tacquard, Alexandre Mansour, Alexandre Godon, et al.Thrombosis and Haemostasis|June 15, 2023
Factors Influencing Anti-Xa Assays: A Multicenter Prospective Study in Critically Ill and Noncritically Ill Patients Receiving Unfractionated HeparinDominique Lasne, Marie Toussaint-Hacquard, Céline Delassasseigne, et al.Blood Advances|May 27, 2026
A comprehensive multicenter study assessing the impact of abelacimab, asundexian and milvexian on coagulation assaysLaurie Goubeau, Emmanuel Curis, Xavier Delavenne, et al.Anaesthesia, Critical Care & Pain Medicine|June 28, 2025
Anticoagulant management in emergency settings: 2024 guidelines from the French Society of Emergency Medicine (SFMU), the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Working Group on Perioperative Haemostasis (GIHP)Delphine Douillet, Alexandre Godon, Geoffroy Rousseau, et al.Journal of Thrombosis and Haemostasis : JTH|August 11, 2024
Sensitivity and specificity of strategies to identify patients with hemostasis abnormalities leading to an increased risk of bleeding before scheduled intervention: the Hemorisk studyNadine Ajzenberg, Dan Longrois, Dorothée Faille, et al.Pageof 10